- Home
- OWLS vs RAPT Comparison
OWLS vs RAPT Comparison
Compare OWLS & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OWLS | RAPT |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 498.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | OWLS | RAPT |
|---|---|---|
| Price | $6.52 | $35.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 58.6K | ★ 365.9K |
| Earning Date | 12-29-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,804,100.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.29 | N/A |
| 52 Week Low | $6.00 | $5.67 |
| 52 Week High | $90.00 | $42.39 |
Technical Indicators
Market Signals| Indicator | OWLS | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.37 |
| Support Level | N/A | $33.01 |
| Resistance Level | N/A | $35.42 |
| Average True Range (ATR) | 0.00 | 2.17 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 83.95 |
Price Performance
Historical ComparisonAbout OWLS OBOOK Holdings Inc.
OBOOK Holdings Inc is focused on using blockchain technology to provide inventive solutions to customers in various sectors, including financial services, hospitality, and e-commerce. Through its e-commerce, hospitality and payments offerings, it is committed to serving businesses and individuals whose commercial activities involve cross-border transactions.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.